Additional microbial contamination has been identified in three drug products at NECC. Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) continue investigating NECC and have discovered bacteria and fungal species in unopened vials of betamethasone, cardioplegia, and triamcinolone solutions. To date, CDC has no reports of laboratory-confirmed cases of illness caused by these products, which were recalled, along with all other NECC products on October 6, 2012. CDC continues to recommend that clinicians remain alert for the possibility that infections may have resulted from injection of NECC products, and that routine laboratory and microbiologic tests, including bacterial and fungal cultures, should be obtained as deemed necessary by treating clinicians. Clinicians should continue to report infections potentially related to NECC products to FDA's MedWatch Program and to state health departments. Additional details are included in a CDC Health Update.